Search Results for: HRAS

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
MAP2K1 mitogen-activated protein kinase kinase 1
  • MAPK3 (ERK1) activation
  • Frs2-mediated activation
  • Signal transduction by L1
  • Uptake and function of anthrax toxins
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • K-252a
  • 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
  • Cobimetinib
  • Bosutinib
  • (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
  • 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
  • PD-0325901
  • N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
  • 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
  • Trametinib
  • Selumetinib
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
ITGB3 integrin subunit beta 3
  • Platelet degranulation
  • Elastic fibre formation
  • PECAM1 interactions
  • Molecules associated with elastic fibres
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Syndecan interactions
  • Syndecan interactions
  • ECM proteoglycans
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Abciximab
  • Eptifibatide
  • Antithymocyte immunoglobulin (rabbit)
  • Levothyroxine
  • Tirofiban
  • Resveratrol
  • Lefradafiban
  • LM-609
  • Fradafiban
  • Ferric maltol
  • Glanzmann thrombasthenia
  • Allograft rejection
MAPK8 mitogen-activated protein kinase 8
  • Activation of BIM and translocation to mitochondria
  • Activation of BMF and translocation to mitochondria
  • NRAGE signals death through JNK
  • NRAGE signals death through JNK
  • NRIF signals cell death from the nucleus
  • Oxidative Stress Induced Senescence
  • FCERI mediated MAPK activation
  • DSCAM interactions
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Activation of the AP-1 family of transcription factors
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-38 signaling
  • WNT5:FZD7-mediated leishmania damping
  • Tamoxifen
  • Minocycline
  • Pyrazolanthrone
  • 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE
  • 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE
  • N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE
  • 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE
  • 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide
  • Halicin
MTOR mechanistic target of rapamycin kinase
  • PIP3 activates AKT signaling
  • Macroautophagy
  • MTOR signalling
  • mTORC1-mediated signalling
  • HSF1-dependent transactivation
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • CD28 dependent PI3K/Akt signaling
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Regulation of PTEN gene transcription
  • Amino acids regulate mTORC1
  • Pimecrolimus
  • Sirolimus
  • Everolimus
  • Rimiducid
  • SF1126
  • XL765
  • Ridaforolimus
  • Temsirolimus
  • Fostamatinib
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
  • PIP3 activates AKT signaling
  • Synthesis of PIPs at the plasma membrane
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Caffeine
  • XL765
  • TG100-115
  • 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
  • Idelalisib
  • Duvelisib
  • Fostamatinib
  • Copanlisib
RAF1 Raf-1 proto-oncogene, serine/threonine kinase
  • Stimuli-sensing channels
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • CD209 (DC-SIGN) signaling
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • Sorafenib
  • LErafAON
  • XL281
  • iCo-007
  • Cholecystokinin
  • Regorafenib
  • Dabrafenib
  • Fostamatinib
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • ATP
  • Caffeine
  • XL765
  • Wortmannin
  • Pilaralisib
  • Alpelisib
  • Copanlisib
  • Ovarian cancer
IL3 interleukin 3
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • RUNX1 regulates transcription of genes involved in interleukin signaling
  • Interleukin receptor SHC signaling
  • Amlexanox
  • Zinc
  • Polaprezinc
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
TLR2 toll like receptor 2
  • ER-Phagosome pathway
  • Beta defensins
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • Regulation of TLR by endogenous ligand
  • Neutrophil degranulation
  • Modulation by Mtb of host immune system
  • Lyme disease vaccine (recombinant OspA)
  • Adapalene
  • S-(Dimethylarsenic)Cysteine
  • Golotimod
  • Tuberculin purified protein derivative
TLR9 toll like receptor 9
  • PI3K Cascade
  • Trafficking and processing of endosomal TLR
  • Toll Like Receptor 9 (TLR9) Cascade
  • Potential therapeutics for SARS
  • TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 dependent cascade initiated on endosome
  • Chloroquine
  • Hydroxychloroquine
  • ISS-1018
  • Golotimod
  • CPG 10101
KRAS KRAS proto-oncogene, GTPase
  • Signaling by moderate kinase activity BRAF mutants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • RUNX3 regulates p14-ARF
  • RAS processing
  • RAS GTPase cycle mutants
  • Signaling downstream of RAS mutants
  • [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID
  • Farnesyl diphosphate
  • MRTX849
  • AMG-510
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
  • Pancreatic cancer
  • Gastric cancer
  • Colorectal cancer
  • Non-small cell lung cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Oral cancer
  • Acute myeloid leukemia (AML)
  • Endometrial Cancer
  • Multiple myeloma
  • Squamous cell carcinoma
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Thyroid cancer
  • Cervical cancer
  • Hepatocellular carcinoma
  • Ovarian cancer
  • Gallbladder cancer
LGALS1 galectin 1
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
  • Mercaptoethanol
  • Thiodigalactoside
  • 1,4-Dithiothreitol
  • Artenimol
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Isoprenaline
  • SF1126
  • Enzastaurin
  • Wortmannin
TP73 tumor protein p73
  • Activation of PUMA and translocation to mitochondria
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Regulation of TP53 Activity through Association with Co-factors
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Zinc
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Hepatocellular carcinoma
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Triglyme
  • Fostamatinib
PRKCI protein kinase C iota
  • Pre-NOTCH Transcription and Translation
  • p75NTR recruits signalling complexes
  • Tight junction interactions
  • Tamoxifen
  • Bisindolylmaleimide I
  • Fostamatinib
QPCT glutaminyl-peptide cyclotransferase
  • Neutrophil degranulation
  • 1-benzylimidazole
  • N-acetylhistamine
  • Glutamine t-butyl ester
ACTG1 actin gamma 1
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Copper
  • Artenimol
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
AFDN afadin, adherens junction formation factor
  • (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one

Page 2 out of 8 pages